T-cell-engaging bispecific antibodies in cancer
NWCJ van de Donk, S Zweegman - The Lancet, 2023 - thelancet.com
T-cell-engaging bispecific antibodies (BsAbs) simultaneously bind to antigens on tumour
cells and CD3 subunits on T cells. This simultaneous binding results in the recruitment of T …
cells and CD3 subunits on T cells. This simultaneous binding results in the recruitment of T …
Bispecific antibodies: a mechanistic review of the pipeline
AF Labrijn, ML Janmaat, JM Reichert… - Nature reviews Drug …, 2019 - nature.com
The term bispecific antibody (bsAb) is used to describe a large family of molecules designed
to recognize two different epitopes or antigens. BsAbs come in many formats, ranging from …
to recognize two different epitopes or antigens. BsAbs come in many formats, ranging from …
Bi-and trispecific immune cell engagers for immunotherapy of hematological malignancies
A Tapia-Galisteo, L Álvarez-Vallina, L Sanz - Journal of Hematology & …, 2023 - Springer
Immune cell engagers are engineered antibodies with at least one arm binding a tumor-
associated antigen and at least another one directed against an activating receptor in …
associated antigen and at least another one directed against an activating receptor in …
Disrupting N-glycan expression on tumor cells boosts chimeric antigen receptor T cell efficacy against solid malignancies
B Greco, V Malacarne, F De Girardi, GM Scotti… - Science translational …, 2022 - science.org
Immunotherapy with chimeric antigen receptor (CAR)–engineered T cells showed
exceptional successes in patients with refractory B cell malignancies. However, first-in …
exceptional successes in patients with refractory B cell malignancies. However, first-in …
[HTML][HTML] A review of bispecific antibodies and antibody constructs in oncology and clinical challenges
Bispecific antibodies (bsAbs) are antibodies that bind two distinct epitopes to cancer.. For
use in oncology, one bsAb has been approved and 57 bsAbs are in clinical trials, none of …
use in oncology, one bsAb has been approved and 57 bsAbs are in clinical trials, none of …
The present and future of bispecific antibodies for cancer therapy
Bispecific antibodies (bsAbs) enable novel mechanisms of action and/or therapeutic
applications that cannot be achieved using conventional IgG-based antibodies …
applications that cannot be achieved using conventional IgG-based antibodies …
Chromosome 1q21 abnormalities in multiple myeloma
Abstract Gain of chromosome 1q (+ 1q) is one of the most common recurrent cytogenetic
abnormalities in multiple myeloma (MM), occurring in approximately 40% of newly …
abnormalities in multiple myeloma (MM), occurring in approximately 40% of newly …
Bispecific antibodies in multiple myeloma: present and future
G Lancman, DL Sastow, HJ Cho, S Jagannath… - Blood cancer …, 2021 - AACR
Despite many recent advances in therapy, there is still no plateau in overall survival curves
in multiple myeloma. Bispecific antibodies are a novel immunotherapeutic approach …
in multiple myeloma. Bispecific antibodies are a novel immunotherapeutic approach …
[HTML][HTML] Bispecific T-cell engagers: towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their …
D Ellerman - Methods, 2019 - Elsevier
Bispecific molecules redirecting the cytotoxicity of T-cells are a growing class of therapeutics
with numerous molecules being tested in clinical trials. However, it has been a long way …
with numerous molecules being tested in clinical trials. However, it has been a long way …
A T-cell–redirecting bispecific G-protein–coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma
K Pillarisetti, S Edavettal, M Mendonça… - Blood, The Journal …, 2020 - ashpublications.org
T-cell–mediated approaches have shown promise in myeloma treatment. However, there
are currently a limited number of specific myeloma antigens that can be targeted, and …
are currently a limited number of specific myeloma antigens that can be targeted, and …